Star Imaging and Path Lab Ltd
Incorporated in 2004, Star Imaging and Path Lab Limited is a healthcare company providing diagnostic services across a wide range of medical tests.[1]
- Market Cap ₹ 125 Cr.
- Current Price ₹ 71.8
- High / Low ₹ 152 / 46.0
- Stock P/E 6.33
- Book Value ₹ 61.4
- Dividend Yield 0.00 %
- ROCE 34.7 %
- ROE 40.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 1.17 times its book value
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.9%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 222 days.
- Working capital days have increased from 43.5 days to 121 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE SME IPO
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 69 | 58 | 79 | 84 | 86 | |
| 54 | 52 | 55 | 54 | 52 | |
| Operating Profit | 15 | 6 | 23 | 29 | 34 |
| OPM % | 21% | 10% | 30% | 35% | 40% |
| 0 | 0 | 1 | 0 | 1 | |
| Interest | 2 | 2 | 3 | 3 | 3 |
| Depreciation | 4 | 3 | 5 | 5 | 5 |
| Profit before tax | 9 | 1 | 16 | 21 | 27 |
| Tax % | 33% | 35% | 23% | 26% | |
| 6 | 1 | 12 | 16 | 20 | |
| EPS in Rs | 41.93 | 3.87 | 82.80 | 11.80 | 12.96 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 7% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 36% |
| TTM: | 37% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 34% |
| Last Year: | 41% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 14 | 17 |
| Reserves | 17 | 17 | 30 | 34 | 89 |
| 30 | 27 | 31 | 33 | 20 | |
| 10 | 16 | 20 | 18 | 23 | |
| Total Liabilities | 58 | 61 | 82 | 98 | 150 |
| 15 | 19 | 22 | 21 | 26 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 43 | 42 | 60 | 77 | 124 | |
| Total Assets | 58 | 61 | 82 | 98 | 150 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 14 | 5 | 18 | -6 | |
| -4 | -7 | -7 | -4 | |
| -7 | -5 | 2 | -0 | |
| Net Cash Flow | 3 | -7 | 13 | -10 |
| Free Cash Flow | 10 | -2 | 11 | -10 |
| CFO/OP | 119% | 95% | 95% | -2% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 85 | 110 | 152 | 222 |
| Inventory Days | ||||
| Days Payable | ||||
| Cash Conversion Cycle | 85 | 110 | 152 | 222 |
| Working Capital Days | 6 | -13 | 23 | 121 |
| ROCE % | 6% | 34% | 35% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| CT Scan Machines Infrastructure Number ・Standalone data |
|
||
| MRI Machines Infrastructure Number ・Standalone data |
|||
| Number of PPP Centers Number ・Standalone data |
|||
| Pathology Tests Number of Tests |
|||
| Radiology Tests - CT Scan Number of Tests |
|||
| Radiology Tests - MRI Number of Tests |
|||
| Radiology Tests - X-Ray Number of Tests |
|||
| Total Diagnostic Centers Number ・Standalone data |
|||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for To Consider And Approve Audited (Standalone And Consolidated) Financial Results Of The Company For The Half And Financial Year Ended March 31, 2026.
15 May - Board meets 22 May 2026 to approve audited FY26 results; trading window reopens 48 hours after declaration.
-
Intimation For Appointment Of Investor And Public Relations Agency Of The Company Under The SEBI (LODR), Regulations 2015 ('Listing Regulations')
14 May - Appointed NeoAtlas Capital Advisory LLP as investor relations advisor effective 14 May 2026.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
14 May - Monitoring agency report for quarter ended March 31, 2026 shows nil deviations and Rs 5.14 crore utilised.
-
Annual Disclosure Confirming Non-Applicability Pertaining To Fund Raising By Issuance Of Debt Securities By Large Entities
8 May - Company confirms it is not a Large Corporate as of March 31, 2026.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
24 Apr - Company confirms it is not a Large Corporate; initial debt disclosure not required for FY2026-27.
Business Profile[1]
Star Imaging and Path Lab Limited (originally Janta X-Ray Clinic) is a Delhi-based diagnostic healthcare service provider offering pathology, radiology, cardiology, and neurology services. The company operates through B2C, B2B, and B2G models, with NABL-accredited facilities.